US
Weight-loss medications
Evidence-based guidance on weight-loss medications including GLP-1 receptor agonists like Wegovy, Ozempic, and Mounjaro. Find reliable information on efficacy, side effects, NHS availability, and how these medications work as part of a balanced approach to weight loss. Our content is developed by healthcare professionals and nutritionists to support informed decisions about medication-assisted weight loss in the UK.
Weight-loss medications
The Wegovy pill: what it is, how it works, and when it’s coming to the UK
The Wegovy pill (oral semaglutide 25 mg) is the first GLP-1 pill approved for weight loss. FDA-approved in the U.S., UK approved in June 2026.
Weight-loss medications
The Wegovy pill vs Foundayo: which oral GLP-1 medication is better for weight loss?
Wegovy pill vs Foundayo: 13.6% vs 11.2% average weight loss in trials. Wegovy pill needs an empty stomach; Foundayo can be taken any time.
Weight-loss medications
Oral weight-loss medications in the UK: a 2026 guide to the Wegovy pill, Foundayo, and Rybelsus
Three oral GLP-1 weight-loss pills compared. Wegovy pill (13.6%) and Foundayo (11.2%) expected in UK late 2026 and 2027; Rybelsus available now for type 2.
Weight-loss medications
Foundayo (orforglipron): what it is, how it works, and when it’s coming to the UK
Foundayo (orforglipron) is a daily GLP-1 pill for weight loss with no fasting requirements. FDA-approved April 2026. Average weight loss 11.2% at 72 weeks.
Weight-loss medications
Retatrutide vs Wegovy: which works better for weight loss?
Retatrutide produced 28.7% weight loss in trials vs Wegovy 7.2 mg's 20.7%. Retatrutide isn't UK-approved yet; Wegovy is the current option.
Weight-loss medications
Retatrutide side effects: what the trials show and how to manage them
Retatrutide's main side effects in trials: nausea (43%), heart rate increase of ~6.7 bpm, and dysesthesia (20.9%) at the 12 mg dose. Not yet UK-approved.
Weight-loss medications
Retatrutide vs Mounjaro
In trials, retatrutide reached 28.7% weight loss vs Mounjaro's 22.5%. Retatrutide isn't UK-approved yet, so Mounjaro is the current option.
Weight-loss medications
CagriSema vs Mounjaro: how they compare on weight loss, side effects, and UK availability
Mounjaro produced more weight loss than CagriSema in REDEFINE 4: 25.5% vs 23.0% over 84 weeks. Only Mounjaro is licensed and available in the UK.
Weight-loss medications
What is CagriSema? A UK guide to Novo Nordisk’s new weight-loss injection
CagriSema: 22.7% weight loss in REDEFINE 1, the highest for any Novo Nordisk obesity drug. Lost head-to-head to Mounjaro. Not yet UK-approved.
Weight-loss medications
When will CagriSema be available in the UK?
CagriSema isn't yet available in the UK. No MHRA filing as of May 2026. Private launch likely 2026-2027, NHS access from 2028.
As seen on
As seen on
